Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

60 output Results for «Solubility»

ReviewOpen access2026

Terpenoids: A Comprehensive Review on Biosynthesis, Applications and Enhancement Strategies for Translational Research

International Journal of Molecular Sciences · vol. 27 (20) · 9280-9280

There is growing interest in natural bioactive compounds as potentially safer and more sustainable sources of therapeutic agents. Terpenoids, one of the most structurally diverse and biologically active classes of natural products, are derived from repeating isoprene units and possess a broad range of pharmacological and industrial applications. This review provides a comprehensive overview of recent advances in terpenoid biosynthesis, structural classification, and therapeutic applications. It also discusses emerging approaches for enhancing large-scale production, improving functional efficacy, and overcoming pharmacokinetic limitations. Attention is given to terpenoids currently undergoing clinical evaluation, along with their progress toward commercial development. Despite substantial preclinical evidence supporting their therapeutic potential, the clinical translation of many terpenoids remains limited. Key challenges include poor aqueous solubility, low permeability, slow dissolution, and high lipophilicity, which can collectively restrict systemic bioavailability and therapeutic efficacy. Moreover, only a relatively small proportion of biologically active terpenoids have progressed to advanced stages of clinical development, highlighting a considerable gap between experimental findings and clinical application. This review integrates current knowledge of terpenoid biosynthesis, biological activities, production strategies, and translational development while highlighting sustainable and scientifically driven approaches that may facilitate their future therapeutic and commercial utilization.

terpenoidsterpenoid biosynthesisisoprene unitsnatural products
ArticleClosed2026

Integrated In Silico and In Vitro Discovery of a VEGFR-2-Targeted Anticancer Benzanilide Lead

Journal of Computational Biophysics and Chemistry · 1-20

The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.

VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
ArticleOpen access202522citation· Semantic Scholar

RETRACTED: A review on sustainable non-thermal approaches for pea protein: Pre-treatment, extraction, modification, and applications

Food Chemistry X · vol. 29 · 102608-102608

Pea protein is gaining global attention as a sustainable, plant-based alternative to animal proteins due to its lower environmental impact. However, conventional thermal processing methods can degrade its functional and nutritional properties. This review explores sustainable non-thermal approaches for pea protein processing, focusing on pre-treatment, extraction, and modification. Ultrasonication is the most effective extraction technique and offers higher protein content (82.76 to 85.76%) compared to alkaline, air classification, and enzymatic methods. For protein modification, enzymatic treatment proves most effective, enhancing digestibility by 20.86 to 22.50% and solubility by 64.28 to 66.55%, while preserving structural integrity, compared to other non-thermal techniques. We critically assess the impact of these techniques on protein conformation, allergenicity reduction, and bioavailability and discuss their applications in food formulations and plant-based alternatives. Despite technological advances, significant research gaps remain in understanding molecular structural changes and challenges in industrial scalability. Future studies should focus on scaling processing methods.

pea proteinnon-thermal processingsonicationprotein extraction
ReviewOpen (repository)20259citation· Semantic Scholar

Anticancer Potential of Wogonin: A Comprehensive Treatise

Food Science & Nutrition · vol. 13 (11) · e71128-e71128

Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.

wogoninanticancer activityflavonoidsapoptosis
ReviewClosed20257citation· Semantic Scholar

Harnessing the Power of D‐Alpha‐Tocopheryl Polyethylene Glycol Succinate‐Based Nanoparticles for Targeted Breast Cancer Therapy

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · vol. 17 (6) · e70040-e70040

Breast cancer (BC) continues to be the most common cancer affecting women globally, posing significant therapeutic challenges due to limited therapeutic efficacy, non-specific drug targeting, systemic toxicity, and the emergence of chemoresistance. These hurdles emphasize the critical need for novel and effective treatment strategies. Nanomedicine has revolutionized cancer therapy, especially D-alpha-tocopheryl polyethylene glycol succinate (TPGS)-based nanoparticles (TPGS-NPs), which have emerged as a promising strategy due to their enhanced therapeutic potential. TPGS, an amphiphilic derivative of Vitamin E, not only enhances the solubility, stability, and bioavailability of lipophilic drugs but also exhibits intrinsic anti-BC properties. The incorporation of TPGS into NPs significantly enhances their physicochemical properties. Further, the engineering of TPGS-NPs with targeting ligands significantly improves their specificity towards cancer cells. Also, TPGS-NPs show great potential to improve photothermal and photodynamic therapies due to their excellent physicochemical properties. Moreover, TPGS-NPs demonstrate an excellent ability for gene (plasmid DNA, siRNA, and miRNA) delivery by enhancing stability and transfection efficiency. This review explores the multifaceted role of TPGS and the role of different TPGS-NPs in circumventing the limitations of conventional chemotherapy in BC treatment. Overall, developing TPGS-NPs offers a versatile and multifaceted approach to achieve better therapeutic outcomes against BC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

breast cancertargeted drug deliveryphotothermal therapyphotodynamic therapy
ArticleOpen access20256citation· Semantic Scholar

A novel thiadiazole-based dual inhibitor of carbonic anhydrase-IX and epidermal growth factor receptor targeting cancer: A combined in silico and in vitro approach

Journal of Chemical Research · vol. 49 (6)

The co-expression of epidermal growth factor receptor and carbonic anhydrase-IX in aggressive tumors such as triple-negative breast cancer contributes to therapeutic resistance through proliferative signaling and hypoxia-mediated adaptation. Dual inhibition of these targets represents a promising strategy for overcoming tumor resilience and enhancing treatment efficacy. A novel thiadiazole-based hybrid molecule ( N -(4-(( E )-1-((( Z )-5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3 H )-ylidene)hydrazono)ethyl)phenyl)benzamide), ASTPB, was rationally designed through pharmacophore modeling, followed by molecular docking and molecular dynamics simulations for 200 ns to assess its dual-binding affinity to epidermal growth factor receptor and carbonic anhydrase-IX. Molecular dynamics simulations confirmed the stability of ASTPB complexes with both epidermal growth factor receptor and carbonic anhydrase-IX, as indicated by stable root mean square deviation values, consistent radius of gyration, and persistent hydrogen bonding, which supported its strong dual-binding affinity. Further quantum chemical analysis via density functional theory supported the electronic stability and reactive potential of ASTPB. In addition, in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and toxicity) predictions indicated low toxicity, a wide safety margin, limited solubility and absorption, and overall favorable metabolic and distribution profiles. ASTPB was synthesized and exhibited potent dual inhibition of carbonic anhydrase-IX and epidermal growth factor receptor, with IC₅₀ values of 0.046 ± 0.007 µM and 0.059 ± 0.009 µM, respectively, comparable to standard inhibitors. In cytotoxicity assays, ASTPB was examined across several cancer cell lines (HePG-2, MCF-7, HCT-116, PC-3, MDA-MB-231), with the greatest efficacy against MDA-MB-231 (IC₅₀ = 18.15 µM) and minimal toxicity toward normal WI-38 cells (IC₅₀ = 72.46 µM). Cell cycle analysis revealed G0/G1 phase arrest, while Annexin V/PI staining indicated early apoptosis in 76.7% of cells. Molecular assays confirmed upregulation of Bax and caspase-3 (3.7-fold each) and downregulation of Bcl-2 (1.97-fold), indicating activation of the intrinsic apoptotic pathway. In conclusion, ASTPB is a promising dual carbonic anhydrase-IX/epidermal growth factor receptor inhibitor with selective cytotoxicity and potent pro-apoptotic activity, particularly in triple-negative breast cancer models. These findings support its potential as a multi-targeted therapeutic lead in the treatment of hypoxia-adapted, epidermal growth factor receptor–driven malignancies.

carbonic anhydrase IXepidermal growth factor receptortriple-negative breast cancerpharmacophore modeling
ArticleClosed20253citation

VEGFR-2-Targeted Semisynthetic Theobromine Derivative: A Computer-Aided Drug Design (CADD) Approach

Journal of Computational Biophysics and Chemistry · vol. 25 (11) · 2043-2063

Angiogenesis plays a pivotal role in tumor progression, and VEGFR-2 is a well-established therapeutic target in cancer treatment. In this study, we report the design, semi-synthesis, and comprehensive evaluation of a novel theobromine-based VEGFR-2 inhibitor, T-1-BHEPA [([Formula: see text]-[Formula: see text]-(4-(1-(2-benzoylhydrazono)ethyl)phenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1[Formula: see text]-purin-1-yl)acetamide]. A structure-based computer-aided drug design (CADD) approach was employed, beginning with pharmacophore modeling, followed by in-depth computational validation. The binding affinity of T-1-BHEPA to VEGFR-2 was examined through molecular docking, 400 ns molecular dynamics (MD) simulations, MM-GBSA binding energy calculations, and protein–ligand interaction fingerprinting (ProLIF) interaction analysis, all of which confirmed a strong and stable interaction with the VEGFR-2 active site. DFT calculations indicated T-1-BHEPA’s stability and reactivity. Before semi-synthesis, in silico ADMET evaluations highlighted good solubility, nonhepatotoxicity, low CYP2D6 interaction and noncarcinogenic potential, along with a favorable chronic toxicity profile. Consistent with these predictions, T-1-BHEPA exhibited potent in vitro VEGFR-2 inhibition (IC 50 [Formula: see text] 0.059 ± 0.006 [Formula: see text]M), comparable to sorafenib (IC 50 [Formula: see text] 0.045 ± 0.006 [Formula: see text]M). T-1-BHEPA demonstrated selective cytotoxicity against a panel of cancer cell lines, with pronounced activity against MDA-MB-231 (IC 50 [Formula: see text] 11.64 ± 1.0 [Formula: see text]M), and a high selectivity index (SI > 6.7) over normal WI-38 cells. Cell cycle analysis revealed G2/M phase arrest, while apoptosis assays confirmed significant increases in early and late apoptotic populations. These effects were further supported by molecular markers, including elevated caspase-3, upregulation of Bax and downregulation of Bcl-2, consistent with activation of the intrinsic apoptotic pathway. Overall, T-1-BHEPA represents a rationally designed and biologically validated VEGFR-2 inhibitor with promising anticancer efficacy and safety, warranting further preclinical development.

VEGFR-2 inhibitorstheobromine derivativesangiogenesiscancer
ArticleOpen (repository)20252citation· Semantic Scholar

A Novel Facile and Efficient Prophylaxis Avenue of Chitosan Oligosaccharide/PLGA Based Polydatin Loaded Nanoparticles Against Bleomycin-Induced Lung Inflammation in Experimental Rat Model

AAPS PharmSciTech · vol. 26 (1) · 35-35

Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects. Its clinical applications are hindered due to poor aqueous solubility, low bioavailability, and rapid metabolism by first-pass effect. Herein, we report the development of a novel chitosan oligosaccharide-coated PD-loaded Poly dl-lactide-co-glycolide nanoparticles (COS-coated PD/PLGA NPs) against a bleomycin-induced pulmonary inflammation in a rat model. The NPs exhibited a small particle size of 188.57 ± 5.68 nm and a high zeta potential of + 18.13 ± 2.75 mV with spherical architecture and sustained release pattern of PD. In vivo studies in bleomycin-induced lung inflammation in a rat model revealed the superior prophylactic activity of COS-coated PD/PLGA NPs over the free drug (PD) as demonstrated by histopathological and immunohistochemical analyses, alongside biochemical assays evaluating oxidative stress biomarkers and inflammatory cytokine levels. Overall, the optimized COS-coated PD/PLGA NPs formulation offers a promising prophylactic platform against many respiratory diseases.

polydatinPLGA nanoparticlesbleomycin-induced lung injurylung inflammation
ReviewOpen access202454citation· Semantic Scholar

Recent Advancements in Gallic Acid-Based Drug Delivery: Applications, Clinical Trials, and Future Directions

Pharmaceutics · vol. 16 (9) · 1202-1202

Gallic acid (GA) is a well-known herbal bioactive compound found in many herbs and foods like tea, wine, cashew nuts, hazelnuts, walnuts, plums, grapes, mangoes, blackberries, blueberries, and strawberries. GA has been reported for several pharmacological activities, such as antioxidant, inflammatory, antineoplastic, antimicrobial, etc. Apart from its incredible therapeutic benefits, it has been associated with low permeability and bioavailability issues, limiting their efficacy. GA belongs to BCS (Biopharmaceutics classification system) class III (high solubility and low probability). In this context, novel drug delivery approaches played a vital role in resolving these GA issues. Nanocarrier systems help improve drug moiety's physical and chemical stability by encapsulating them into a lipidic or polymeric matrix or core system. In this regard, researchers have developed a wide range of nanocarrier systems for GA, including liposomes, transfersomes, niosomes, dendrimers, phytosomes, micelles, nanoemulsions, metallic nanoparticles, solid lipid nanoparticles (SLNs), nanoparticles, nanostructured lipid carriers, polymer conjugates, etc. In the present review, different search engines like Scopus, PubMed, ScienceDirect, and Google Scholar have been referred to for acquiring recent information on the theme of the work. Therefore, this review paper aims to emphasize several novel drug delivery systems, patents, and clinical updates of GA.

gallic aciddrug delivery systemsnanocarriersbioavailability enhancement
ReviewOpen access202446citation· Semantic Scholar

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

Beilstein Journal of Nanotechnology · vol. 15 · 1473-1497

Phytochemicals, naturally occurring compounds in plants, possess a wide range of therapeutic properties, including antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. However, their clinical application is often hindered by poor water solubility, low bioavailability, rapid metabolism, and instability under physiological conditions. Polymer lipid hybrid nanoparticles (PLHNPs) have emerged as a novel delivery system that combines the advantages of both polymeric and lipid-based nanoparticles to overcome these challenges. This review explores the potential of PLHNPs to enhance the delivery and efficacy of phytochemicals for biomedical applications. We discuss the obstacles in the conventional delivery of phytochemicals, the fundamental architecture of PLHNPs, and the types of PLHNPs, highlighting their ability to improve encapsulation efficiency, stability, and controlled release of the encapsulated phytochemicals. In addition, the surface modification strategies to improve overall therapeutic efficacy by site-specific delivery of encapsulated phytochemicals are also discussed. Furthermore, we extensively discuss the preclinical studies on phytochemical encapsulated PLHNPs for the management of different diseases. Additionally, we explore the challenges ahead and prospects of PLHNPs regarding their widespread use in clinical settings. Overall, PLHNPs hold strong potential for the effective delivery of phytochemicals for biomedical applications. As per the findings from pre-clinical studies, this may offer a promising strategy for managing various diseases.

lipid-polymer hybrid nanoparticlesphytochemical deliveryphytochemicalsbioavailability enhancement
ArticleOpen access202435citation· Semantic Scholar

Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy

International Journal of Pharmaceutics X · vol. 7 · 100232-100232

Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.

vildagliptinsolid lipid nanoparticlesOcusertocular drug delivery
ReviewOpen access202423citation· Semantic Scholar

An insight into pharmaceutical challenges with ionic liquids: where do we stand in transdermal delivery?

Frontiers in Bioengineering and Biotechnology · vol. 12 · 1454247-1454247

Ionic liquids (ILs) represent an exciting and promising solution for advancing drug delivery platforms. Their unique properties, including broad chemical diversity, adaptable structures, and exceptional thermal stability, make them ideal candidates for overcoming challenges in transdermal drug delivery. Despite encountering obstacles such as side reactions, impurity effects, biocompatibility concerns, and stability issues, ILs offer substantial potential in enhancing drug solubility, navigating physiological barriers, and improving particle stability. To propel the use of IL-based drug delivery in pharmaceutical innovation, it is imperative to devise new strategies and solvents that can amplify drug effectiveness, facilitate drug delivery to cells at the molecular level, and ensure compatibility with the human body. This review introduces innovative methods to effectively address the challenges associated with transdermal drug delivery, presenting progressive approaches to significantly improve the efficacy of this drug delivery system.

ionic liquidstransdermal drug deliveryskin permeationdrug solubility enhancement
ArticleOpen access202421citation· Semantic Scholar

Exploring the therapeutic potential of lipid-based nanoparticles in the management of oral squamous cell carcinoma

Exploration of Targeted Anti-tumor Therapy · vol. 5 (6) · 1223-1246

Oral squamous cell carcinoma (OSCC) is a highly malignant and invasive tumor with significant mortality and morbidity. Current treatment modalities such as surgery, radiotherapy, and chemotherapy encounter significant limitations, such as poor targeting, systemic toxicity, and drug resistance. There is an urgent need for novel therapeutic strategies that offer targeted delivery, enhanced efficacy, and reduced side effects. The advent of lipid-based nanoparticles (LNPs) offers a promising tool for OSCC therapy, potentially overcoming the limitations of current therapeutic approaches. LNPs are composed of biodegradable and biocompatible lipids, which minimize the risk of toxicity and adverse effects. LNPs can encapsulate hydrophobic drugs, improving their solubility and stability in the biological environment, thereby enhancing their bioavailability. LNPs demonstrate significantly higher ability to encapsulate lipophilic drugs than other nanoparticle types. LNPs offer excellent storage stability, minimal drug leakage, and controlled drug release, making them highly effective nanoplatforms for the delivery of chemotherapeutic agents. Additionally, LNPs can be modified by complexing them with specific target ligands on their surface. This surface modification allows the active targeting of LNPs to the tumors in addition to the passive targeting mechanism. Furthermore, the PEGylation of LNPs improves their hydrophilicity and enhances their biological half-life by reducing clearance by the reticuloendothelial system. This review aims to discuss current treatment approaches and their limitations, as well as recent advancements in LNPs for better management of OSCC.

oral squamous cell carcinomalipid nanoparticlestargeted drug deliverychemotherapy
ReviewOpen access202417citation· Semantic Scholar

Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management

Pharmaceuticals · vol. 17 (2) · 248-248

Disease-modifying anti-rheumatic drugs (DMARDs) is a class of anti-rheumatic medicines that are frequently prescribed to patients suffering from rheumatoid arthritis (RA). Methotrexate, sulfasalazine, hydroxychloroquine, and azathioprine are examples of non-biologic DMARDs that are being used for alleviating pain and preventing disease progression. Biologic DMARDs (bDMARDs) like infliximab, rituximab, etanercept, adalimumab, tocilizumab, certolizumab pegol, and abatacept have greater effectiveness with fewer adverse effects in comparison to non-biologic DMARDs. This review article delineates the classification of DMARDs and their characteristic attributes. The poor aqueous solubility or permeability causes the limited oral bioavailability of synthetic DMARDs, while the high molecular weights along with the bulky structures of bDMARDs have posed few obstacles in their drug delivery and need to be addressed through the development of nanoformulations like cubosomes, nanospheres, nanoemulsions, solid lipid nanoparticles, nanomicelles, liposome, niosomes, and nanostructured lipid carrier. The main focus of this review article is to highlight the potential role of nanotechnology in the drug delivery of DMARDs for increasing solubility, dissolution, and bioavailability for the improved management of RA. This article also focusses on the different aspects of nanoparticles like their applications in biologics, biocompatibility, body clearance, scalability, drug loading, and stability issues.

rheumatoid arthritisdisease-modifying antirheumatic drugsnanotechnologydrug delivery
ReviewOpen access202416citation· Semantic Scholar

Emerging Trends of Nanomedicines in the Management of Prostate Cancer: Perspectives and Potential Applications

Pharmaceutics · vol. 16 (3) · 297-297

Prostate cancer is one of the most life-threatening disorders that occur in males. It has now become the third most common disease all over the world, and emerging cases and spiking mortality rates are becoming more challenging day by day. Several approaches have been used to treat prostate cancer, including surgery, radiation therapy, chemotherapy, etc. These are painful and invasive ways of treatment. Primarily, chemotherapy has been associated with numerous drawbacks restricting its further application. The majority of prostate cancers have the potential to become castration-resistant. Prostate cancer cells exhibit resistance to chemotherapy, resistance to radiation, ADT (androgen-deprivation therapy) resistance, and immune stiffness as a result of activating tumor-promoting signaling pathways and developing resistance to various treatment modalities. Nanomedicines such as liposomes, nanoparticles, branched dendrimers, carbon nanotubes, and quantum dots are promising disease management techniques in this context. Nanomedicines can target the drugs to the target site and enhance the drug's action for a prolonged period. They may also increase the solubility and bioavailability of poorly soluble drugs. This review summarizes the current data on nanomedicines for the prevention and treatment of prostate cancer. Thus, nanomedicine is pioneering in disease management.

prostate cancernanomedicinedrug deliveryliposomes